BSE : 500257
`
`NSE: Lupin
`
`BLOOMBERG: LPC IN
`
`
`REUTERS: LUPN.BO
`
`LUPIN announces settlement with SANTARUS and DEPOMED for GLUMETZA Patent Litigation
`
`Mumbai / Baltimore, February 22, 2012: Pharma major, Lupin Ltd. and its subsidiary, Lupin Pharmaceuticals, Inc.
`(collectively, “Lupin”) announced today, that it has entered into a settlement agreement with Santarus, Inc.
`(NASDAQ:SNTS) and Depomed, Inc. (NASDAQ:DEPO) to resolve pending patent
`litigation
`involving
`GLUMETZA® (extended release metformin tablets) 1000 mg and 500 mg.
`
`The settlement agreement grants Lupin the right to begin selling a generic version of GLUMETZA on February 1,
`2016, or earlier under certain circumstances. GLUMETZA® extended release metformin tablets, 1000 mg and 500 mg
`had annual U.S sales of approximately US$ 71 million, for the twelve months ending December, 2011 (IMS Health
`data). The settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade
`Commission, as well as entry by the U.S. District Court for the Northern District of California of an order dismissing
`the litigation.
`
`Lupin had earlier received the tentative approval for generic GLUMETZA® (Metformin Hydrochloride Extended
`Release Tablets) 1000 mg and 500 mg from the United States Food and Drugs Administration (FDA)in January, 2012.
`Lupin believes it is the first applicant to file an ANDA for GLUMETZA® 1000 mg & 500 mg strengths and as such
`is entitled to 180 days of marketing exclusivity.
`
`About Lupin Limited
`
`Headquartered in Mumbai, India, Lupin is an innovation led transnational pharmaceutical company producing a wide
`range of generic and branded formulations and APIs. The Company today has significant presence in the
`Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAID space in addition to holding
`global leadership positions in the Anti-TB and Cephalosporin segments.
`
`Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS
`Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10
`pharmaceutical player in India, Japan and South Africa (IMS).
`
`For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 Million
`(USD 1.28 Billion) and Rs. 8,626 Million (USD 193 Million) respectively. Please visit http://www.lupinworld.com for
`more information about Lupin Ltd.
`
`About Lupin Pharmaceuticals, Inc.
`
`Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited. Headquartered in Baltimore,
`Maryland, Lupin Pharmaceuticals, Inc. is committed to delivering high-quality, affordable generic medicines and
`branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit
`http://www.lupinpharmaceuticals.com
`
`For further information please contact:
`
`Shamsher Gorawara
`
`Depomed Exhibit 2144, Page 1 of 2
`
`

`
`
`
`Head – Corporate Communications
`Lupin Limited:
`Ph: +91 98 20 338 555
`Email: shamshergorawara@lupinpharma.com
`
`Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
`This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially
`different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure
`of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations
`in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release
`represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release
` Glumetza Extended-release Tablets, 500 mg & 1000 mg are registered copyright of Santarus, Inc.
`
` *
`
`Depomed Exhibit 2144, Page 2 of 2